Amylin Pharmaceuticals and Eli Lilly, joint developers of Exenatide, reported to the American Diabetes Association meeting that their drug copied from the venom of gila monsters helps diabetics lower their blood sugar and lose weight. If successful, the drug would be the first in a new class of incretin mimetics drugs for treating Type 2 diabetes.

Related Summaries